Kymera Therapeutics KYMR
$115.31 −$4.08 (-3.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $124.06 +7.59%
Open$117.89
Prev close$119.39
Day range$114.40 – $119.60
Volume1.28M
Market cap$9.84B
P/E (TTM)–
Dividend yield–
KYMR Stock News
Headlines matching Kymera Therapeutics or the KYMR ticker, most recent first.
- J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $140 Positive
- J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
- J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140
- Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140
- Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $152 Positive
- BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $144 Positive
- Wolfe Research Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Announces Target Price $180 Positive
- J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121
- BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123 Negative
- A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139
- A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $128 to $139
- Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $170 Positive
- Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151 Positive
- Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132
- Analysts' Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)
No comments yet — be the first to weigh in on KYMR.
Sign in to join the discussion.